← Leaderboards
Jeffrey J Molldrem
University Of Texas Md Anderson Can Ctr
$7,910,420
Attributed
$7,910,420
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $628.4K · FY2005–22$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$7,910,420 · 8
By mechanism
P01$3,469,935 · 3
P50$2,772,605 · 3
R01$1,667,880 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Md Anderson Can Ctr
Same institution · by research overlap
- Sara S. Strom$4,426,461
- Razelle Kurzrock$10,423,704
- Stefan Faderl$537,560
- Yong-Jun Liu$11,224,674
Others in their field
Top investigators on “Immunotherapy”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,653,178
- Constance Ann Benson · University Of California, San Diego$150,079,712
- Joseph Sparano · Montefiore Medical Center (Bronx, Ny)$111,361,061
- Robert H Vonderheide · University Of Pennsylvania$84,159,371
- Sharon A Nachman · Johns Hopkins University$74,725,055
- Todd A Alonzo · University Of Colorado Denver/Hsc Denver$72,436,447
Research focus
ImmunotherapyRelapseLeukemiaPre-ClinicalAllogenicAntigensT-Cell ReceptorT-LymphocyteCellsMediatingIn VivoStem Cell TransplantCytotoxic T-LymphocytesAffinityPhenotypeAdoptive Cell TransfersIn VitroMyeloid LeukemiaImmune ResponseLeukocyte ElastasePeptidesBaseDisease RemissionProteinase 3
Grant awards (34)
Cord Blood T Cell Therapy for Myeloid Malignancies$356,063
P01 · FY2022 · CA · contact PI
Project 2: Anti-PR1 Immune Therapy for Myeloid Leukemia$272,373
P50 · FY2022 · CA · contact PI
Cord Blood T Cell Therapy for Myeloid Malignancies$355,822
P01 · FY2021 · CA · contact PI
Project 2: Anti-PR1 Immune Therapy for Myeloid Leukemia$272,373
P50 · FY2021 · CA · contact PI
Cord Blood T Cell Therapy for Myeloid Malignancies$355,740
P01 · FY2020 · CA · contact PI
Project 2: Anti-PR1 Immune Therapy for Myeloid Leukemia$232,219
P50 · FY2020 · CA · contact PI
Cord Blood T Cell Therapy for Myeloid Malignancies$344,961
P01 · FY2019 · CA · contact PI
Project 2: Anti-PR1 Immune Therapy for Myeloid Leukemia$272,373
P50 · FY2019 · CA · contact PI
Cord Blood T Cell Therapy for Myeloid Malignancies$364,440
P01 · FY2018 · CA · contact PI
Project 2: Anti-PR1 Immune Therapy for Myeloid Leukemia$238,193
P50 · FY2018 · CA · contact PI
PR1-specific CB T cells for Patients with Myeloid Malignancies$45,960
P01 · FY2016 · CA · contact PI
PR1-specific CB T cells for Patients with Myeloid Malignancies$297,605
P01 · FY2015 · CA · contact PI
PR1-specific CB T cells for Patients with Myeloid Malignancies$115,490
P01 · FY2014 · CA · contact PI
PR1-specific CB T cells for Patients with Myeloid Malignancies$216,516
P01 · FY2013 · CA · contact PI
Anit-PR1 Immune Therapy for Myeloid Leukemia$196,339
P50 · FY2013 · CA · contact PI
PR1-specific CB T cells for Patients with Myeloid Malignancies$278,810
P01 · FY2012 · CA · contact PI
Adoptive Cellular Therapy for Myeloid Leukemia$234,003
P50 · FY2012 · CA · contact PI
Adoptive Cellular Therapy for Myeloid Leukemia$279,250
P50 · FY2011 · CA · contact PI
Adoptive Cellular Therapy for Myeloid Leukemia$274,932
P50 · FY2010 · CA · contact PI
Adoptive Cellular Therapy for Myeloid Leukemia$298,717
P50 · FY2009 · CA · contact PI
Proteinase 3-Derived Peptide Epitopes to Elicit Cytotoxic T Lymphocytes Targeting$237,149
P01 · FY2009 · CA · contact PI
Adoptive Cellular Therapy for Myeloid Leukemia$201,833
P50 · FY2008 · CA · contact PI
Proteinase 3-Derived Peptide Epitopes to Elicit Cytotoxic T Lymphocytes Targeting$171,655
P01 · FY2008 · CA · contact PI
Proteinase 3-Derived Peptide Epitopes to Elicit Cytotoxic T Lymphocytes Targeting$167,185
P01 · FY2007 · CA · contact PI
Proteinase 3-Derived Peptide Epitopes to Elicit Cytotoxic T Lymphocytes Targeting$162,539
P01 · FY2006 · CA · contact PI
IMMUNOTHERAPY OF LOW RISK MYELODYSPLASTIC SYNDROME$217,875
R01 · FY2005 · CA
Proteinase 3-Derived Peptide Epitopes to Elicit Cytotoxic T Lymphocytes Targeting$0
P01 · FY2005 · CA
IMMUNOTHERAPY OF LOW RISK MYELODYSPLASTIC SYNDROME$217,875
R01 · FY2004 · CA
IMMUNOTHERAPY OF LOW RISK MYELODYSPLASTIC SYNDROME$217,875
R01 · FY2003 · CA
IMMUNOTHERAPY OF LOW RISK MYELODYSPLASTIC SYNDROME$217,875
R01 · FY2002 · CA
PROTEINASE 3 SPECIFIC IMMUNOTHERAPY OF LEUKEMIA$182,536
R01 · FY2002 · CA
IMMUNOTHERAPY OF LOW RISK MYELODYSPLASTIC SYNDROME$264,568
R01 · FY2001 · CA
PROTEINASE 3 SPECIFIC IMMUNOTHERAPY OF LEUKEMIA$177,218
R01 · FY2001 · CA
PROTEINASE 3 SPECIFIC IMMUNOTHERAPY OF LEUKEMIA$172,058
R01 · FY2000 · CA